Monte Carlo analysis reveals enhanced therapeutic effect for 161Tb in micrometastases, suggesting its use in treatment.
¹⁶¹ Tb offers a more efficient subcellular energy deposition profile than ¹⁷⁷Lu. It enables either similar therapeutic effect with fewer decays or enhanced nuclear absorbed dose under equivalent bone marrow toxicity. These results support the use of ¹⁶¹ Tb in targeted radiopharmaceutical therapy, particularly for isolated tumor cells and micrometastases.
No takes yet. Share an insight, caveat, or question.
Velo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: